Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 05 Jan 2018
At a glance
- Drugs Sorafenib (Primary) ; Temsirolimus (Primary)
- Indications Thyroid cancer
- Focus Therapeutic Use
- 02 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 02 Jan 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Jun 2017 Biomarkers information updated